Noribogaine Hydrochloride Drug Due Diligence Report 2026

This Noribogaine Hydrochloride Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Noribogaine Hydrochloride can convert its Small molecule drug profile and NMDA receptor x κ opioid receptor biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Noribogaine Hydrochloride (query alias: Noribogaine Hydrochloride)
Modality / target	Small molecule drug; NMDA receptor x κ opioid receptor; NMDA receptor antagonists, κ opioid receptor antagonists
Highest global status	Phase 2
Originator	DemeRx, Inc.
Active developers	DemeRx NB, Inc., DemeRx, Inc.

The MCP disease footprint includes Opioid-Related Disorders, Substance Abuse, Alcohol Use Disorder. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06480981	Phase 1	Completed	55	Primary endpoint not disclosed in English source
ACTRN12613001064796	Phase 1	Completed	27	Primary endpoint not disclosed in English source
ACTRN12613000539730	Not Applicable	Completed	6	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Randomized, Double-blind, Placebo-controlled Trial to Evaluate Multiple Dose Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Ascending Doses of Noribogaine in Healthy Volunteers.

Phase 1; n=55; evaluation: Not stated in English source. Reported fields: Pharmacokinetics Cmax Day 1(Mean) = 10.4 ng/mL ; Pharmacokinetics Cmax Day 1(Mean) = 22.7 ng/mL

DemeRx Announces Successful Completion of Multiple Ascending Dose Clinical Trial of DMX-1001 for the Treatment of Alcohol Use Disorder (AUD)

Phase 1; n=55; evaluation: Positive. Reported fields: Safety = safe and well-tolerated

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Noribogaine Hydrochloride addresses Opioid-Related Disorders, Substance Abuse, Alcohol Use Disorder. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 3 matched transaction record(s) under the scope “target-level comparable: NMDA receptor x κ opioid receptor.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: NMDA receptor x κ opioid receptor records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
Not disclosed	OrsoBio Announces Acquisition of LXR Inverse Agonist Program for Treatment of Severe Dyslipidemias from Phenex Pharmaceuticals	Preclinical	Financial terms not disclosed
2021-11-04	Inspirna and Bristol Myers Squibb collaborate on a phase Ib/II clinical trial to investigate the efficacy of RGX-104 in combination with Yervoy for the treatment of metastatic endometrial cancer.	Phase 1/2	Financial terms not disclosed
2001-07-18	Exelixis, Inc.announced a collaboration with Bristol-Myers Squibb Company.	Discovery	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Method of treating chemical dependency”. The milestone feed surfaced a patent-application signal described as “Pharmacotherapies for improving treatment adherence after discontinuation of incretin-based therapies”. The milestone feed surfaced a patent-application signal described as “Systems, devices, and methods for event-based knowledge reasoning systems using active and passive sensors for patient monitoring and feedback”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO